Patents by Inventor Vijaykumar KARUPPIAH

Vijaykumar KARUPPIAH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250026829
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Application
    Filed: September 30, 2024
    Publication date: January 23, 2025
    Inventors: Jakub JAWORSKI, Kate ATKIN, Arnaud TECHINE, Vijaykumar KARUPPIAH, Florence SCHLOSSER, Ana PEREIRA RIBEIRO, Chandramouli CHILLAKURI, Nathaniel LIDDY, Andrew CREESE, Martin EBNER
  • Patent number: 12195534
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Grant
    Filed: January 5, 2024
    Date of Patent: January 14, 2025
    Assignee: IMMUNOCORE LIMITED
    Inventors: Nicole Mai, Arnaud Techine, Jakub Jaworski, Kate Atkin, Nathaniel Liddy, Vijaykumar Karuppiah, Ana Pereira Ribeiro, Ana Penas, Andrew Creese, Emma Grant, Stephen Harper, Chandramouli Chillakuri, Eduardo Mateos-Diaz, Tamara Aleksic, Pedro Cuadrado Rodenas
  • Patent number: 12134647
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Grant
    Filed: January 5, 2024
    Date of Patent: November 5, 2024
    Assignee: IMMUNOCORE LIMITED
    Inventors: Jakub Jaworski, Kate Atkin, Arnaud Techine, Vijaykumar Karuppiah, Florence Schlosser, Ana Pereira Ribeiro, Chandramouli Chillakuri, Nathaniel Liddy, Andrew Creese, Martin Ebner
  • Publication number: 20240254228
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Application
    Filed: January 5, 2024
    Publication date: August 1, 2024
    Inventors: Nicole MAI, Arnaud TECHINE, Jakub JAWORSKI, Kate ATKIN, Nathaniel LIDDY, Vijaykumar KARUPPIAH, Ana PEREIRA RIBEIRO, Ana PENAS, Andrew CREESE, Emma GRANT, Stephen HARPER, Chandramouli CHILLAKURI, Eduardo MATEOS-DIAZ, Tamara ALEKSIC, Pedro CUADRADO RODENAS
  • Publication number: 20240228617
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Application
    Filed: January 5, 2024
    Publication date: July 11, 2024
    Inventors: Jakub JAWORSKI, Kate ATKIN, Arnaud TECHINE, Vijaykumar KARUPPIAH, Florence SCHLOSSER, Ana PEREIRA RIBEIRO, Chandramouli CHILLAKURI, Nathaniel LIDDY, Andrew CREESE, Martin EBNER
  • Patent number: 11981945
    Abstract: The present invention relates to a process of producing a monoterpene and/or derivatives thereof. The process comprises the steps of: a) providing a host microorganism genetically engineered to express a bacterial monoterpene synthase (mTS); and b) contacting geranyl pyrophosphate (GPP) with said bacterial mTS to produce said monoterpene and/or derivatives thereof. The present invention also relates to a microorganism for use in producing a monoterpene and/or derivatives thereof and a recombinant microor-ganism adapted to conduct the step of converting geranyl pyrophosphate (GPP) into a monoterpene and/or derivatives thereof by ex-pression of a bacterial mTS. It was shown to produce 1,8 cineole using 1,8 cineole synthase and to produce linalool using linalool synthase, both from Streptomyces clavuligerus.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: May 14, 2024
    Assignee: C3 BIOTECHNOLOGIES LIMITED
    Inventors: Vijaykumar Karuppiah, Nicole G. H. Leferink, Nigel S. Scrutton
  • Publication number: 20210238640
    Abstract: The present invention relates to a process of producing a monoterpene and/or derivatives thereof. The process comprises the steps of: a) providing a host microorganism genetically engineered to express a bacterial monoterpene synthase (mTS); and b) contacting geranyl pyrophosphate (GPP) with said bacterial mTS to produce said monoterpene and/or derivatives thereof. The present invention also relates to a microorganism for use in producing a monoterpene and/or derivatives thereof and a recombinant microor-ganism adapted to conduct the step of converting geranyl pyrophosphate (GPP) into a monoterpene and/or derivatives thereof by ex-pression of a bacterial mTS. It was shown to produce 1,8 cineole using 1,8 cineole synthase and to produce linalool using linalool synthase, both from Streptomyces clavuligerus.
    Type: Application
    Filed: April 23, 2021
    Publication date: August 5, 2021
    Inventors: Vijaykumar KARUPPIAH, Nicole G. H. LEFERINK, Nigel S. Scrutton
  • Publication number: 20200102585
    Abstract: The present invention relates to a process of producing a monoterpene and/or derivatives thereof. The process comprises the steps of: a) providing a host microorganism genetically engineered to express a bacterial monoterpene synthase (mTS); and b) contacting geranyl pyrophosphate (GPP) with said bacterial mTS to produce said monoterpene and/or derivatives thereof. The present invention also relates to a microorganism for use in producing a monoterpene and/or derivatives thereof and a recombinant microorganism adapted to conduct the step of converting geranyl pyrophosphate (GPP) into a monoterpene and/or derivatives thereof by expression of a bacterial mTS. It was shown to produce 1,8 cineole using 1,8 cineole synthase and to produce linalool using linalool synthase, both from Streptomyces clavuligerus.
    Type: Application
    Filed: January 26, 2018
    Publication date: April 2, 2020
    Inventors: Vijaykumar KARUPPIAH, Nicole G. H. LEFERINK, Nigel S. Scrutton